Scientists have developed an "intelligent knife" that can tell surgeons immediately whether the tissue they are cutting is cancerous or not. This has been called a potential 'game-changer' for cancer surgery. Sam Wong elabrotes in his article:
"In the first study to test the invention in the operating theatre, the “iKnife” diagnosed tissue samples from 91 patients with 100 per cent accuracy, instantly providing information that normally takes up to half an hour to reveal using laboratory tests.
The findings, by researchers at Imperial College London, are published today in the journal Science Translational Medicine. The study was funded by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre, the European Research Council and the Hungarian National Office for Research and Technology.
In cancers involving solid tumours, removal of the cancer in surgery is generally the best hope for treatment. The surgeon normally takes out the tumour with a margin of healthy tissue. However, it is often impossible to tell by sight which tissue is cancerous. One in five breast cancer patients who have surgery require a second operation to fully remove the cancer. In cases of uncertainty, the removed tissue is sent to a lab for examination while the patient remains under general anaesthetic." Read the full article here
iBRA-NET – No Innovation without Evaluation
In October the first working meeting of the iBRA Network took place.
59 surgeons have applied to be involved and each has been assigned to one of the four studies in development under the iBRANet banner. The steering groups for each of these met in parallel session on October 29th to finalise protocols, and CRFs with a view to recruitment starting in the New Year. An overarching steering group has also been set up which also had its first meeting on October 29th.
There is now a pathway for breast surgical studies from the ABS Innovation Group, to the Sandpit session and on to iBRANet for implementation.
The 4 studies currently in development are:
Phase II Cohort Study of pre-pectoral implant base breast reconstruction.
Map Bra: CI: Julia.firstname.lastname@example.org
Phase II cohort study of a new mesh for implant reconstruction – Fortiva
3D-SI to assess aesthetic outcome after breast reconstruction: CI: Jennifer.email@example.com
The design and assessment of objective 3d cosmetic assessment of breast reconstruction.
A National Audit of Magseed® localisation of breast lesions. CI James.firstname.lastname@example.org
These studies will be opening to recruitment early in the New Year
If you would like to recruit to any of these studies please contact Clare Brannigan at email@example.com
- Over diagnosis and treatment
- Optimising selection for neoadjuvant therapies and subsequent surgery
- Reducing re-operation rates for breast conserving surgery
- Generating evidence for the clinical and cost-effectiveness of breast reconstruction and novel interventions
- Determining optimal axillary management, especially post-neoadjuvant treatment
- Defining and standardising indications for risk-reducing surgery